PT-141 (Bremelanotide) Overdose & Accidental Excess Dose

What PT-141 (Bremelanotide) Is and How It Works

PT-141, sold as Vyleesi, is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is also used off-label for male erectile dysfunction. Unlike phosphodiesterase-5 inhibitors, bremelanotide acts centrally on the brain rather than directly on genital vasculature.

Understanding its mechanism matters enormously for interpreting overdose physiology.

Melanocortin Receptor Pharmacology

Bremelanotide binds with high affinity to melanocortin receptors MC1R, MC3R, MC4R, and MC5R. MC4R activation in the hypothalamus is thought to drive the pro-sexual effect by modulating dopaminergic and serotonergic pathways in reward circuitry. The drug is structurally derived from alpha-melanocyte-stimulating hormone (alpha-MSH), a neuropeptide that also regulates appetite, inflammation, and autonomic tone. PMID 12811370

MC1R activation produces the transient skin flushing and hyperpigmentation sometimes reported with repeated dosing. MC3R and MC4R activation in the nucleus of the solitary tract contributes to nausea and the pressor response. These receptor interactions are not blocked by any currently approved reversal agent, which is why management of an excess dose is purely supportive.

Central vs. Peripheral Action

Because bremelanotide acts centrally, its therapeutic window differs from peripherally acting sexual-function drugs. A dose that is modestly above the therapeutic range does not simply produce "more desire." It produces amplified autonomic side effects: sharper blood-pressure increases, more intense nausea, and in some reports, prolonged flushing. The brain-blood barrier penetrance of bremelanotide after subcutaneous injection is sufficient to stimulate hypothalamic MC4R within 45 minutes of administration, which is why the label specifies that timing window. FDA label, NDA 210557

Pharmacokinetics Relevant to Overdose Timing

After a 1.75 mg subcutaneous injection, peak plasma concentration (Cmax) is reached in approximately 1 hour. Mean elimination half-life is about 2.7 hours. Metabolism occurs primarily via non-enzymatic hydrolysis of the peptide backbone, with minor contributions from the cytochrome P450 system. A principal metabolite, bremelanotide-met (also designated as metabolite M5), retains some melanocortin activity and may extend the duration of side effects beyond what the parent half-life alone would predict. In a patient who has injected more than the approved dose, total melanocortin stimulation could persist for 6 to 10 hours before falling below a clinically meaningful threshold.

Evidence Base: What the RECONNECT Trials Tell Us About Dose-Response

The RECONNECT Phase 3 program enrolled 1,247 premenopausal women across two identically designed, 24-week randomized controlled trials. Both trials compared bremelanotide 1.75 mg subcutaneous to placebo on the Female Sexual Function Index desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) total score. PMID 31060191

Efficacy Findings

Both trials met their co-primary endpoints. Statistically significant improvements in desire scores and distress scores were observed in the bremelanotide arm versus placebo (P<0.001 for both co-primary endpoints in Trial 1; P<0.001 for both in Trial 2). The number of satisfying sexual events increased by a mean of 0.5 events per month more than placebo, a modest but statistically strong difference.

Safety Data Directly Informing Overdose Risk

Nausea occurred in 40.4% of the bremelanotide group compared to 1.3% of placebo, and was the primary reason 8.9% of patients discontinued treatment. Flushing occurred in 20.4% versus 1.7% placebo. Headache occurred in 11.0% versus 3.5%. Blood pressure was measured at 45 minutes post-dose and again at 12 hours. Mean systolic blood pressure rose by approximately 6 mmHg and mean diastolic by approximately 4 mmHg at 45 minutes, returning to baseline by 12 hours. Individual patient data showed outliers with larger pressor responses, particularly in women with a BMI <27 kg/m² who may have had higher unbound plasma drug concentrations.

The FDA's pharmacology review noted that adverse events were dose-dependent across the Phase 2 dose-ranging studies. Higher doses of 3.5 mg and 7 mg (studied in earlier Phase 2 work) produced substantially more nausea, more vomiting, and more pronounced cardiovascular effects than the 1.75 mg approved dose. This dose-response gradient is the clearest signal that an excess dose is not simply wasted drug; it creates a predictable toxidrome.

Recognizing an Accidental Excess Dose: The Clinical Presentation

An "overdose" in the PT-141 context most commonly means one of three scenarios: a patient injects two doses in close succession, a compounded formulation is prepared at a higher concentration than intended, or a patient misunderstands the directions and uses the device twice in one session.

Cardiovascular Signs

The pressor effect is the most medically consequential feature of excess bremelanotide exposure. Patients may notice a throbbing headache, facial flushing, warmth in the neck and chest, or subjective palpitations. Measured blood pressure elevations of 15 to 25 mmHg systolic above baseline are plausible at twice the approved dose, extrapolating linearly from the dose-response data. Patients with pre-existing hypertension face proportionally greater risk. The Vyleesi prescribing information explicitly contraindicates use in patients with known cardiovascular disease because the pressor response cannot be reliably buffered by a compromised cardiovascular system. FDA label, NDA 210557

Gastrointestinal Signs

Nausea is the dominant symptom at therapeutic doses. With excess exposure, vomiting is likely. Onset typically begins 30 to 60 minutes after injection and may persist for 2 to 4 hours. Severe vomiting carries a secondary risk: volume depletion, which can interact unpredictably with the elevated sympathetic tone from MC4R stimulation, potentially causing orthostatic hypotension once the acute pressor phase wanes.

Neurological and Integumentary Signs

Headache is common even at therapeutic doses (11% in RECONNECT). At excess doses, headache intensity increases. Focal neurological symptoms are not expected from the pharmacology, but any new neurological sign in a patient with elevated blood pressure should prompt emergency evaluation to exclude hypertensive emergency. Transient hyperpigmentation (darkening of the face, gums, or breasts) results from MC1R stimulation and is not a sign of systemic toxicity, but it can persist for weeks after even a single dose and may be more pronounced after excess exposure. PMID 12811370

What Is Not Expected

PT-141 does not act on opioid receptors, GABA receptors, or the cardiac conduction system in any way that resembles classic drug toxidromes. Respiratory depression, pinpoint pupils, and QT prolongation are not part of the bremelanotide pharmacological signature. A patient presenting with those findings after reported PT-141 use should be evaluated for a co-ingested substance.

Step-by-Step Management of Accidental Excess Dose

There is no antidote. Management follows a three-tier structure based on symptom severity.

Tier 1: Mild Presentation (Nausea, Flushing, Mild Headache, BP Rise <20 mmHg Systolic)

1. Keep the patient in a supine or semi-reclined position to reduce orthostatic stress.
2. Obtain a baseline blood pressure reading and repeat every 30 minutes for the first 2 hours.
3. For nausea, ondansetron 4 mg oral or sublingual is a reasonable first-line choice; it does not interact with the melanocortin system. Metoclopramide is an alternative but carries a small risk of extrapyramidal effects and is not preferred.
4. Oral hydration with electrolyte-containing fluids if nausea permits.
5. Avoid additional medications that raise blood pressure (pseudoephedrine, triptans, stimulants) for at least 12 hours.
6. Monitor until blood pressure returns to within 10 mmHg of the patient's personal baseline.

Tier 2: Moderate Presentation (Vomiting, BP Rise of 20 to 40 mmHg Systolic, Severe Headache)

1. Call Poison Control: 1-800-222-1222. A toxicologist can provide real-time guidance and flag any unusual features.
2. IV access and normal saline at a maintenance rate if the patient cannot tolerate oral fluids.
3. Ondansetron 4 mg IV if oral route is not feasible.
4. Blood pressure monitoring every 15 minutes.
5. Short-acting antihypertensives are an option if sustained systolic BP exceeds 180 mmHg, but this decision belongs with an emergency physician who can evaluate the full clinical picture. Avoid agents that cause reflex tachycardia in a patient who is already sympathetically stimulated.
6. Transport to an emergency department if symptoms do not begin improving within 90 minutes.

Tier 3: Severe Presentation (Systolic BP >180 mmHg, Intractable Vomiting, Chest Pain, or Any Neurological Change)

Call 911 immediately. These presentations require emergency department evaluation and monitoring for hypertensive end-organ damage. The differential at this severity level includes hypertensive emergency, hemorrhagic stroke (very rare but elevated BP is a modifiable risk factor), and myocardial ischemia. Standard emergency hypertension protocols apply. The treating physician should be informed that bremelanotide is a cyclic peptide metabolized by non-CYP hydrolysis, so no drug interaction with most standard emergency medications is expected, but the pressor mechanism is not alpha-adrenergic and will not respond to alpha-blockade in the way that a pheochromocytoma crisis would.

Special Populations with Elevated Risk After Excess Dosing

Certain patients face disproportionately greater risk from a PT-141 excess dose. These groups warrant a lower threshold for emergency evaluation.

Patients with Hypertension

The RECONNECT trials excluded patients on antihypertensives for uncontrolled hypertension. A patient who uses bremelanotide despite having elevated baseline BP and then accidentally doubles the dose starts from a higher cardiovascular risk point. Even the standard approved dose raises systolic BP by a mean of 6 mmHg; from a baseline of 155/95, a 15 to 20 mmHg additional rise could reach hypertensive crisis territory.

Patients Using Compounded PT-141

FDA-approved Vyleesi delivers a fixed 1.75 mg dose from a prefilled autoinjector. Compounded PT-141 vials (widely available through peptide pharmacies and telehealth prescribers) may be prepared at concentrations of 10 mg/mL or higher. A miscalculated volume draw of 0.5 mL instead of 0.175 mL delivers approximately 5 mg, nearly three times the approved dose. This is arguably the most common pathway to clinically significant excess exposure. Patients using compounded formulations must be counseled on exact volume calculations before each use. FDA label, NDA 210557

Patients with Low Body Weight

Lower body weight reduces the volume of distribution for a fixed subcutaneous dose, producing higher plasma concentrations. RECONNECT subgroup analyses and the FDA pharmacology review both noted that adverse event rates were numerically higher in lower-weight participants, consistent with this pharmacokinetic reasoning.

Pregnant Patients

Bremelanotide is contraindicated in pregnancy. Animal reproduction studies showed embryo-fetal developmental toxicity at doses producing exposures lower than the human therapeutic exposure. Any patient with a possible pregnancy who has taken an excess dose requires obstetric evaluation. PMID 31060191

Long-Term and Repeated-Dose Concerns

Single-dose overdose is the acute concern, but repeated suprapherapeutic use carries its own risks.

Hyperpigmentation

MC1R activation by bremelanotide stimulates melanocytes in skin and mucous membranes. The Vyleesi label notes that hyperpigmentation of the face, gums, and breasts occurred in 1% of patients using the drug at therapeutic doses over 24 weeks. With repeated excess dosing, this rate and severity would be expected to increase. The hyperpigmentation is typically reversible after stopping the drug but may take several weeks to months to fade.

Cardiovascular Cumulative Load

Each dose produces a transient BP spike that resolves by 12 hours. Using the drug more frequently than approved (for example, daily rather than as-needed) or at higher doses adds repeated cardiovascular stress that, in a patient with borderline vascular health, could accelerate adverse remodeling. No long-term cardiovascular outcome data for bremelanotide exist beyond the 52-week open-label extension of RECONNECT, which did not detect a signal for adverse cardiac events at the approved dose.

Nausea Tolerance

Interestingly, nausea severity in RECONNECT appeared to decrease with repeated use for some patients, suggesting partial tachyphylaxis at the level of central melanocortin signaling. This tolerance pattern does not eliminate the nausea risk at excess doses; it only moderates it at the approved dose over time.

Reporting an Adverse Event

Any clinically significant reaction from bremelanotide, whether at the approved dose or after accidental excess, should be reported to the FDA's MedWatch program. Prescribers can file at FDA MedWatch. This reporting matters because post-market safety signals for a drug approved in 2019 are still being characterized, and cardiovascular events in real-world users with broader comorbidity profiles than the trial population may surface patterns not detectable in the controlled trial setting.

Poison Control centers (1-800-222-1222 in the United States) maintain up-to-date toxicology protocols and can advise both patients and clinicians in real time. All calls are free and confidential. CDC Poison Control data

Prescriber Guidance: Reducing Accidental Excess Dose Risk

Prescribers play an active role in preventing the accidental overdose scenarios described above. Several steps reduce risk before the patient ever fills the prescription.

Detailed injection training at the point of prescribing, including a demonstration of the autoinjector or, for compounded vials, a supervised practice draw with a placebo-filled syringe, eliminates a large share of dosing errors. Written instructions specifying the exact volume in milliliters (not just milligrams) for any compounded formulation should accompany every prescription. Patients should be told explicitly that a second injection the same day is not appropriate under any circumstances. Cardiovascular baseline assessment, including resting blood pressure on at least two readings, should be documented before the first prescription.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction states: "Clinicians should inform patients that bremelanotide can cause a transient increase in blood pressure and a decrease in heart rate after each injection, which are reasons to avoid its use in those with cardiovascular disease." Endocrine Society CPG